A successful late-stage trial of a new treatment that nearly doubled survival for patients with the deadly pancreatic cancer received a standing ovation from doctors and other global oncology experts ...

For a long time, the likelihood of surviving pancreatic cancer has been extremely low. For patients who were diagnosed with metastatic pancreatic cancer between 2015 and 2021, about 97% died within ...

For a long time, the likelihood of surviving pancreatic cancer has been extremely low. For patients who were diagnosed with metastatic pancreatic cancer between 2015 and 2021, about 97% died within ...

A new, experimental medication nearly doubled overall survival rates for patients with advanced pancreatic cancer, according to the results of a study published Sunday. Researchers say the findings ...

A new medication performed remarkably well in a phase 3 clinical trial for treating pancreatic cancer. The drug daraxonrasib reduced the risk of death by nearly half, as well as shrank tumors in ...

A major new pancreatic cancer pill has nearly doubled survival time in a new study, giving doctors fresh hope against one of the deadliest forms of cancer.

For decades, pancreatic cancer has been one of the most lethal cancers, with few effective treatment options. A new drug, daraxonrasib, targets the KRAS mutation that fuels most pancreatic ...

A study co-led by UCLA found patients who received daraxonrasib, an investigational, first-in-class oral drug designed to block one of the primary drivers of pancreatic cancer, lived a median of 13.2 ...

Add Yahoo as a preferred source to see more of our stories on Google. Terri Truere (left) sits on an examination table as Dr. David Ellison performs a checkup during an appointment at Roper St.

Add Yahoo as a preferred source to see more of our stories on Google. What makes promising pancreatic cancer drug different from chemotherapy? 01:54 A new, experimental medication nearly doubled ...